An independent Centers for Disease Control and Prevention advisory committee today recommended immediate resumption of the administration of Johnson & Johnson’s COVID-19 vaccine in the U.S. The vaccine maker would add a warning to its labeling materials about the risk of rare blood clots known as thrombosis with thrombocytopenia syndrome. The recommendation, which passed by a 10-4 vote with one abstention, now goes to the CDC for its approval. The Food and Drug Administration will amend Johnson & Johnson’s emergency use authorization to indicate that women under the age of 50 should be aware of the risk of blood clots from the vaccine.

CDC’s Clinician Outreach and Communication Activity will hold a Zoom call Tuesday, April 27 at 2 p.m. ET to discuss the latest evidence on thrombosis with thrombocytopenia syndrome after the administration of the Johnson & Johnson vaccine. Access the live webinar here, a recording of which will be available several hours after the live event ends.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…